Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03824483 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Name: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) — clinical trial record (NCT03824483)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorMemorial Sloan Kettering Cancer Center

Started2019-02-22

View on ClinicalTrials.gov ↗

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.

Amendment history 1 change detected by DataLookout

2026-09-04

Enrollment closed, study ongoing

Trial Details

NCT Number	NCT03824483
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: Roche-Genentech, Massachusetts General Hospital, BeOne Medicines
Conditions	Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
Enrollment	230 participants
Start Date	2019-02-22
Primary Completion	2027-02 (estimated)
Study Completion	2027-02 (estimated)
Updated on ClinicalTrials.gov	2026-09-03